Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
|Articles|November 19, 2018
- Dermatology Times, November 2018 (Vol. 39, No. 11)
- Volume 39
- Issue 11
A guide to wound care
Author(s)Dermatology Times Staff
Advertisement
In this table, we cover the basics of wound care, such as reducing bioburden, reducing edema and maintaining a moist wound environment. This information was gathered from a 2014 article from the journal, Plastic Surgical Nursing, in which Marcia Spear, DNP, ACNP-BC, CWS, CPSN, addressed the “Principles of Wound Care - Back to Basics.”
(Click here for a
)
Articles in this issue
almost 8 years ago
Low-dose bleomycin injections result in curious side effectalmost 8 years ago
7 Safety recommendations for tattoo removalalmost 8 years ago
Being older helps skin heal with less scarringalmost 8 years ago
Topical sirolimus shows positive results in two studiesalmost 8 years ago
Wound healing in psoriasis, multiple sclerosisalmost 8 years ago
Classifying diabetic foot ulcersalmost 8 years ago
Role of protease targets in wound healing uncertainalmost 8 years ago
Allograft Tissue Research Grant program taking applicantsalmost 8 years ago
Verrica develops a solution for common wartsalmost 8 years ago
Sarecycline approved for moderate-to-severe acneAdvertisement
Related to this article
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.
Genetic study links higher BMI to looking older, but causality stays unclear; Mendelian randomization flags shared signals and candidate genes needing validation.
Merz Aesthetics adds two FDA-approved Belotero HA fillers for midface volume and lip fullness, promising natural movement and long-lasting results.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
Guselkumab met primary and major secondary endpoints in the phase 4 STAR study, improving axial PsA symptoms and MRI-confirmed inflammation.
Three experimental hair loss mechanisms are moving through late-stage trials for the first time in decades, and the data are worth knowing before patients ask.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
3
Dr. Charrow Highlights Earlier Biologic Use and Deroofing in Hidradenitis Suppurativa
4
FAQ: Everything Clinicians (and Their Patients) Want to Know About the Hair Loss Pipeline
5